Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry

Gastroenterology. 2022 Jan;162(1):316-319.e5. doi: 10.1053/j.gastro.2021.09.011. Epub 2021 Sep 14.

Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group:
Richard B Gearry, Gilaad G Kaplan, Michele Kissous-Hunt, James D Lewis, Siew C Ng, Jean-Francois Rahier, Walter Reinisch, Flavio Steinwurz

¹ The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ryan.ungaro@mssm.edu.
² Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: erica.brenner@unchealth.unc.edu.
³ The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

No abstract available

MeSH terms